Lyell Immunopharma/LYEL

$2.56

-6.9%
-
1D1W1MYTD1YMAX

About Lyell Immunopharma

Lyell Immunopharma, Inc. is a clinical-stage T-cell reprogramming company advancing a diverse pipeline of cell therapies for patients with solid tumors. The Company is engaged in enrolling a Phase I clinical trial evaluating a ROR1-targeted CAR T-cell therapy in patients with relapsed refractory triple-negative breast cancer and non-small cell lung cancer (NSCLC) and a second Phase I clinical trial evaluating reprogrammed tumor infiltrating lymphocytes (TIL) in patients with advanced melanoma, NSCLC and colorectal cancer. The technologies powering its product candidates are designed to address barriers that limit consistent and long-lasting responses to cell therapy for solid tumors: T-cell exhaustion and lack of durable stemness, which includes the ability to persist and self-renew to drive durable tumor cytotoxicity. The Company is applying its proprietary ex vivo genetic and epigenetic reprogramming technologies to address these barriers in order to develop medicines.

Ticker

LYEL

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology & Drugs

CEO

Richard Klausner

Employees

224

Headquarters

South san francisco, United States
Website
lyell.com

LYEL Metrics

BasicAdvanced
$706M
Market cap
-
P/E ratio
-$0.91
EPS
-
Beta
-
Dividend rate
$706M
$3.97
$1.32
881K
16.511
-29%
-32.93%
-30.21%
10,385.02
1.171
1.171
-99.92%
-23.89%
-74.41%

What the Analysts think about LYEL

Analyst Ratings

Majority rating from 4 analysts.
Buy

Price Targets

Average projection from 3 analysts.
147.27% upside
High $9.00
Low $4.00
$2.56
Current price
$6.33
Average price target

LYEL Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
0% profit margin
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$0
NaN%
Net income
-$61M
14.56%
Profit margin
0%
NaN%

LYEL Earnings Performance

Earnings per share (EPS)

Company profitability
Missed by 14.29%
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-$0.26
-$0.20
-$0.20
-$0.24
-
Expected
-$0.27
-$0.25
-$0.23
-$0.21
-$0.19
Surprise
-4.88%
-20%
-12.28%
14.29%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

FAQs

What’s the current market cap for Lyell Immunopharma stock?

Lyell Immunopharma (LYEL) has a market cap of $706M as of May 29, 2024.

What is the P/E ratio for Lyell Immunopharma stock?

The price to earnings (P/E) ratio for Lyell Immunopharma (LYEL) stock is 0 as of May 29, 2024.

Does Lyell Immunopharma stock pay dividends?

No, Lyell Immunopharma (LYEL) stock does not pay dividends to its shareholders as of May 29, 2024.

When is the next Lyell Immunopharma dividend payment date?

Lyell Immunopharma (LYEL) stock does not pay dividends to its shareholders.

What is the beta indicator for Lyell Immunopharma?

Lyell Immunopharma (LYEL) does not currently have a Beta indicator.

What is the Lyell Immunopharma stock price target?

The target price for Lyell Immunopharma (LYEL) stock is $6.33, which is 147.27% above the current price of $2.56. This is an average based on projections from 3 analysts, and represents their view of what the stock price could be in 12 or 18 months. This should not be seen as investment advice - Lightyear does not carry out investment research.

Buy or sell Lyell Immunopharma stock

Buy or sell Lyell Immunopharma stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing